Morgan Stanley Downgrades Acelyrin Inc to Equalweight
(Updated - September 13, 2023 4:44 AM EDT) Morgan Stanley (NYSE:MS) analyst downgraded Acelyrin Inc (SLRN) from Overweight to Equalweight with a price target of $19.00 (from $39.00).The...
Neutral
or
ACELYRIN News & Analysis
-
-
Acelyrin crashes 60% as lead product misses in study; seen as a 'big positive' for MoonLake
Acelyrin (NASDAQ:SLRN) shares plummeted by 58% in premarket trading following disappointing results from a clinical trial of its lead product, izokibep. This drug is designed for patients...
-
H.C. Wainwright maintains ACELYRIN at 'buy' with a price target of $30.00
An analyst from H.C. Wainwright maintained ACELYRIN (NASDAQ: SLRN) at 'buy' with a price target of $30.00 from a prior price target of %currency%%price%. Prior to this rating, ACELYRIN...
-
After-hours movers: Oracle sinks after results, outlook
After-Hours Stock Movers: ACELYRIN Inc (NASDAQ:SLRN) (Nasdaq: SLRN) 62% LOWER; announced top-line results from Part B of a Phase 2b/3 trial evaluating izokibep for the treatment of...
-
Acelyrin Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa Doesn't Hit Primary Endpoint
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced...
-
Acelyrin Halted, News Pending
Acelyrin (SLRN) Halted, News Pending
-
Morgan Stanley maintains ACELYRIN at 'overweight' with a price target of $39.00
An analyst from Morgan Stanley maintained ACELYRIN (NASDAQ: SLRN) at 'overweight' with a price target of $39.00 from a prior price target of %currency%%price%. Prior to this rating,...
-
H.C. Wainwright initiates coverage of ACELYRIN at 'buy' with a price target of $44.00
An analyst from H.C. Wainwright initiated coverage of ACELYRIN (NASDAQ: SLRN) at 'buy' with a price target of $44.00. Prior to this rating, ACELYRIN had 4 buy ratings, 0 hold ratings,...
-
ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023
LOS ANGELES, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative...
-
Acelyrin Appoints Ken Lock as Chief Commercial Officer
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the...
-
Cava Group raises price range as IPO gears up
Investing.com -- Cava Group is gearing up for its initial public offering later this week, raising its price range on Monday. The Mediterranean-style restaurant chain disclosed in a...
-
Acelyrin risk/reward 'skewed to the upside'
ACELYRIN Inc (NASDAQ:SLRN) was initiated at Overweight with a $29 price target by Morgan Stanley in a note Tuesday. Analysts told investors that the company's late-stage immunology...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
